Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
← catalyst calendarNCT05557838 · readout in 42 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
214actual
Sites
29
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-15 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: Durvalumab — also filed as MEDI4736
- Drug: Tremelimumab — also filed as There is no other names for tremelimumab.
Primary outcome
what the primary-completion date above is the date OF≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1
measured From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 44months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed